Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease
Summary
Summary of guidance Donepezil, galantamine and rivastigmine are recommended as options for the treatment of moderate Alzheimer's disease only. Memantine is not recommended as an option for people with moderately severe to severe Alzheimer's disease unless it is being used as part of a clinical tria ...
Update 26 August 2009
NICE has today announced that, following consultation with stakeholders on the economic model that underpinned NICE’s 2006 guidance on the use of drugs to treat Alzheimer’s disease, the resulting guidance remains unchanged.
In accordance with the Court of Appeal’s ruling on the economic model used in the technology appraisal of drugs for the treatment of Alzheimer's disease, NICE released the fully executable version of the model to stakeholders for their comment in November 2008. Having fully reviewed all the resulting comments the independent Appraisal Committee concluded that, although a number of technical inaccuracies were highlighted and amendments were made to the economic model, these were not sufficient to change the original conclusion that these treatments are not cost effective in the mild stages of the disease. Consultees then had a chance to appeal against this decision but no appeals were received.
NICE guidance on the use of donepezil, galantamine and rivastigmine and memantine for the treatment of Alzheimer's disease therefore remains unchanged and the drugs continue to be recommended only for people with moderate Alzheimer’s disease.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in September 2009
About this guidance
Technology appraisals TA111
Issued: September 2007
How this guidance was produced